# Profound Medical Corp.: financial statements, quarterly

PROF · Nasdaq · CIK 1628808 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prof.md) · [Financials](/companies/prof/financials.md) · [Filings](/companies/prof/filings.md) · [Insiders](/companies/prof/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/prof/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.2](/filings/0001410578-25-001112.md) | [2.0](/filings/0001410578-25-001809.md) | [2.5](/filings/0001104659-25-111378.md) | [4.0 d](/filings/0001410578-25-000300.md) | [2.3](/filings/0001410578-25-001112.md) | [2.0](/filings/0001410578-25-001809.md) | [5.1](/filings/0001104659-25-111378.md) | [6.7 d](/filings/0001104659-26-024153.md) | [5.3](/filings/0001104659-26-057198.md) | [2.5](/filings/0001104659-26-092066.md) |
| Cost of revenue | $m | [0.6](/filings/0001410578-25-001112.md) | [0.8](/filings/0001410578-25-001809.md) | [1.0](/filings/0001104659-25-111378.md) | [1.2 d](/filings/0001104659-26-024153.md) | [0.8](/filings/0001104659-26-057198.md) | [0.6](/filings/0001104659-26-092066.md) | [1.4](/filings/0001104659-25-111378.md) | [2.0 d](/filings/0001104659-26-024153.md) | [1.5](/filings/0001104659-26-057198.md) | [0.5](/filings/0001104659-26-092066.md) |
| Gross profit | $m | [0.9](/filings/0001410578-25-001112.md) | [1.4](/filings/0001410578-25-001809.md) | [1.8](/filings/0001104659-25-111378.md) | [3.0 d](/filings/0001104659-26-024153.md) | [1.9](/filings/0001104659-26-057198.md) | [1.6](/filings/0001104659-26-092066.md) | [3.9](/filings/0001104659-25-111378.md) | [4.0 d](/filings/0001104659-26-024153.md) | [3.8](/filings/0001104659-26-057198.md) | [1.9](/filings/0001104659-26-092066.md) |
| Research and development | $m | [3.9](/filings/0001410578-25-001112.md) | [4.2](/filings/0001410578-25-001809.md) | [4.2](/filings/0001104659-25-111378.md) | [4.6 d](/filings/0001104659-26-024153.md) | [4.8](/filings/0001104659-26-057198.md) | [6.1](/filings/0001104659-26-092066.md) | [5.4](/filings/0001104659-25-111378.md) | [4.3 d](/filings/0001104659-26-024153.md) | [5.3](/filings/0001104659-26-057198.md) | [5.7](/filings/0001104659-26-092066.md) |
| Selling, general and administrative | $m | [4.8](/filings/0001410578-25-001112.md) | [5.1](/filings/0001410578-25-001809.md) | [6.6](/filings/0001104659-25-111378.md) | [6.7 d](/filings/0001104659-26-024153.md) | [8.2](/filings/0001104659-26-057198.md) | [9.3](/filings/0001104659-26-092066.md) | [7.4](/filings/0001104659-25-111378.md) | [7.1 d](/filings/0001104659-26-024153.md) | [6.6](/filings/0001104659-26-057198.md) | [7.4](/filings/0001104659-26-092066.md) |
| Operating income | $m | [(7.9)](/filings/0001410578-25-001112.md) | [(7.8)](/filings/0001410578-25-001809.md) | [(9.0)](/filings/0001104659-25-111378.md) | [(8.3) d](/filings/0001104659-26-024153.md) | [(11.2)](/filings/0001104659-26-057198.md) | [(13.8)](/filings/0001104659-26-092066.md) | [(8.9)](/filings/0001104659-25-111378.md) | [(7.4) d](/filings/0001104659-26-024153.md) | [(8.0)](/filings/0001104659-26-057198.md) | [(11.1)](/filings/0001104659-26-092066.md) |
| Income tax | $m | [0.0](/filings/0001410578-25-001112.md) | [0.0](/filings/0001410578-25-001809.md) | [0.2](/filings/0001104659-25-111378.md) | [(0.2) d](/filings/0001104659-26-024153.md) | [0.0](/filings/0001104659-26-057198.md) | [0.1](/filings/0001104659-26-092066.md) | [0.1](/filings/0001104659-25-111378.md) | [0.0 d](/filings/0001104659-26-024153.md) | [0.0](/filings/0001104659-26-057198.md) | [0.1](/filings/0001104659-26-092066.md) |
| Net income | $m | [(6.6)](/filings/0001104659-25-111378.md) | [(6.9)](/filings/0001104659-25-111378.md) | [(9.4)](/filings/0001104659-25-111378.md) | [(4.9) d](/filings/0001104659-26-024153.md) | [(10.7)](/filings/0001104659-26-092066.md) | [(15.7)](/filings/0001104659-26-092066.md) | [(8.0)](/filings/0001104659-25-111378.md) | [(8.2) d](/filings/0001104659-26-024153.md) | [(7.1)](/filings/0001104659-26-092066.md) | [(9.5)](/filings/0001104659-26-092066.md) |
| Diluted EPS | $ per share | [0.27](/filings/0001410578-25-001112.md) | [0.28](/filings/0001410578-25-001809.md) | [0.38](/filings/0001104659-25-111378.md) | not reported | [0.36](/filings/0001104659-26-057198.md) | [(0.52)](/filings/0001104659-26-092066.md) | [0.26](/filings/0001104659-25-111378.md) | not reported | [0.19](/filings/0001104659-26-057198.md) | [(0.26)](/filings/0001104659-26-092066.md) |
| Basic EPS | $ per share | [0.27](/filings/0001410578-25-001112.md) | [0.28](/filings/0001410578-25-001809.md) | [0.38](/filings/0001104659-25-111378.md) | not reported | [0.36](/filings/0001104659-26-057198.md) | [(0.52)](/filings/0001104659-26-092066.md) | [0.26](/filings/0001104659-25-111378.md) | not reported | [0.19](/filings/0001104659-26-057198.md) | [(0.26)](/filings/0001104659-26-092066.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [46.5](/filings/0001410578-24-000149.md) | [26.2](/filings/0001410578-25-000300.md) | not reported | not reported | not reported | [54.9](/filings/0001104659-26-024153.md) | [46.4](/filings/0001410578-25-001112.md) | [35.2](/filings/0001410578-25-001809.md) | [24.8](/filings/0001104659-25-111378.md) | [59.7](/filings/0001104659-26-092066.md) | [50.3](/filings/0001104659-26-057198.md) | [38.3](/filings/0001104659-26-092066.md) |
| Current assets | $m | [62.0](/filings/0001410578-24-000149.md) | [41.9](/filings/0001410578-25-000300.md) | not reported | not reported | not reported | [69.1](/filings/0001104659-26-024153.md) | [59.9](/filings/0001410578-25-001112.md) | [48.8](/filings/0001410578-25-001809.md) | [41.5](/filings/0001104659-25-111378.md) | [76.1](/filings/0001104659-26-092066.md) | [69.5](/filings/0001104659-26-057198.md) | [58.9](/filings/0001104659-26-092066.md) |
| Total assets | $m | [64.4](/filings/0001410578-24-000149.md) | [44.0](/filings/0001410578-25-000300.md) | not reported | not reported | not reported | [70.2](/filings/0001104659-26-024153.md) | [60.9](/filings/0001410578-25-001112.md) | [49.7](/filings/0001410578-25-001809.md) | [42.3](/filings/0001104659-25-111378.md) | [77.5](/filings/0001104659-26-092066.md) | [73.5](/filings/0001104659-26-057198.md) | [62.4](/filings/0001104659-26-092066.md) |
| Current liabilities | $m | [4.2](/filings/0001410578-24-000149.md) | [6.4](/filings/0001410578-25-000300.md) | not reported | not reported | not reported | [6.6](/filings/0001104659-26-024153.md) | [5.3](/filings/0001410578-25-001112.md) | [5.7](/filings/0001410578-25-001809.md) | [9.9](/filings/0001104659-25-111378.md) | [6.1](/filings/0001104659-26-092066.md) | [10.6](/filings/0001104659-26-057198.md) | [9.1](/filings/0001104659-26-092066.md) |
| Total liabilities | $m | [12.4](/filings/0001410578-24-000149.md) | [12.7](/filings/0001410578-25-000300.md) | not reported | not reported | not reported | [9.8](/filings/0001104659-26-024153.md) | [10.1](/filings/0001410578-25-001112.md) | [10.4](/filings/0001410578-25-001809.md) | [10.2](/filings/0001104659-25-111378.md) | [11.0](/filings/0001104659-26-092066.md) | [14.0](/filings/0001104659-26-057198.md) | [12.6](/filings/0001104659-26-092066.md) |
| Long-term debt | $m | [7.2](/filings/0001410578-25-000300.md) | [5.0](/filings/0001410578-25-000300.md) | not reported | not reported | not reported | [2.9](/filings/0001104659-26-024153.md) | [4.5](/filings/0001410578-25-001112.md) | [4.5](/filings/0001410578-25-001809.md) | [4.5](/filings/0001104659-25-111378.md) | [4.5](/filings/0001104659-26-092066.md) | [4.5](/filings/0001104659-26-057198.md) | [4.5](/filings/0001104659-26-092066.md) |
| Current portion of debt | $m | not reported | [2.1](/filings/0001410578-25-000300.md) | not reported | not reported | not reported | [1.7](/filings/0001104659-26-024153.md) | not reported | not reported | [4.5](/filings/0001104659-25-111378.md) | not reported | [4.5](/filings/0001104659-26-057198.md) | [4.5](/filings/0001104659-26-092066.md) |
| Shareholders' equity | $m | [52.6](/filings/0001410578-25-000300.md) | [31.2](/filings/0001104659-26-024153.md) | [45.5](/filings/0001104659-25-111378.md) | [38.9](/filings/0001104659-25-111378.md) | [30.7](/filings/0001104659-25-111378.md) | [60.4](/filings/0001104659-26-092066.md) | [50.8](/filings/0001104659-26-092066.md) | [39.3](/filings/0001104659-26-092066.md) | [32.1](/filings/0001104659-25-111378.md) | [66.4](/filings/0001104659-26-092066.md) | [59.4](/filings/0001104659-26-092066.md) | [49.8](/filings/0001104659-26-092066.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: ifrs-full:CurrentAssets, us-gaap:AssetsCurrent
- Total assets: ifrs-full:Assets, us-gaap:Assets
- Current liabilities: ifrs-full:CurrentLiabilities, us-gaap:LiabilitiesCurrent
- Total liabilities: ifrs-full:Liabilities, us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.5)](/filings/0001410578-25-001112.md) | [(6.2) d](/filings/0001410578-25-001809.md) | [(6.8) d](/filings/0001104659-25-111378.md) | [(5.9) d](/filings/0001104659-26-024153.md) | [(8.3)](/filings/0001104659-26-057198.md) | [(13.7) d](/filings/0001104659-26-092066.md) | [(9.6) d](/filings/0001104659-25-111378.md) | [(6.6) d](/filings/0001104659-26-024153.md) | [(8.6)](/filings/0001104659-26-057198.md) | [(11.3) d](/filings/0001104659-26-092066.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [24.3](/filings/0001410578-25-001112.md) | [24.4](/filings/0001410578-25-001809.md) | [24.5](/filings/0001104659-25-111378.md) | [30.0](/filings/0001104659-26-057198.md) | [30.1](/filings/0001104659-26-092066.md) | [30.1](/filings/0001104659-25-111378.md) | [36.3](/filings/0001104659-26-057198.md) | [36.4](/filings/0001104659-26-092066.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 36,532,594 at 2026-08-06, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-092066.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.